Clinical evaluation of radioactive stents
Restenosis, the major problem after stent implantation, is caused by in-stent neointimal hyperplasia. A number of metbods and techniques have been studied during the last ten years to address tbis issue, but in-stent restenosis has remained at a rate of 15-25% in most of tbe clinical trials. Several experimental and clinical trials showed that brachytherapy, following a balloon angioplasty or stent implantation, reduced restenosis by inhibiting neointimal hyperplasia. Several in-vitro experiments and animal studies demonstrated a reduction of in-stent restenosis after the implantation of 32p B-particle emitting radioactive stents. The research objective of this tbesis was to evaluate whether the implantation of radioactive stents in patients with coronary artery disease could reduce in-stent restenosis. In order for radioactive stents to become an accepted treatment in the current clinical practice its safety, feasibility, efficacy, mechanism of action, and side effects needed to be investigated.
|Publisher||Erasmus MC: University Medical Center Rotterdam|
|Promotor||Serruys, P.W.J.C. (Patrick)|
|Sponsor||Netherlands Heart Foundation|
|Keywords||cardiology, radioactive stents, stenosis|
Wardeh, A.J.. (2001, September 21). Clinical evaluation of radioactive stents. Erasmus MC: University Medical Center Rotterdam. Retrieved from http://hdl.handle.net/1765/23524